LISATA THERAPEUTICS, INC.(LSTA)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
LISATA THERAPEUTICS, INC. (LSTA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LSTA at 15.7/100 on a 32-signal composite quality model, placing it at rank #2,849 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), LISATA THERAPEUTICS, INC. reports net income of $-2.9M, free cash flow of $-2.6M. Top institutional holders of LSTA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Yakira Capital Management, CSS, based on the most recent SEC filings. LSTA trades on the Nasdaq exchange and files with the SEC under CIK 320017. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LSTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LISATA THERAPEUTICS, INC. directly from SEC EDGAR.
AI Quality Score
15.7/100
AI Rank
#2,849
Revenue
$0.00
Net Income
$-2.9M
Free Cash Flow
$-2.6M
LSTA key financials by period
LISATA THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$170.0K
$-16.6M
—
FY 2024
10-K
$1.0M
$-20.0M
—
FY 2016
10-K
$35.3M
$-32.7M
-83.6%
FY 2015
10-K
$22.5M
—
—
FY 2014
10-K
$17.9M
$-54.9M
—
FY 2013
10-K
$14.7M
$-39.0M
—
Institutions holding LSTA
Institutional investors reporting a position in LISATA THERAPEUTICS, INC. on SEC Form 13F.
